Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases

Current Topics in Medicinal Chemistry

Volumn 9, Issue 15, 2009, Pages 1447-1461

  Brandt, Gary E L ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Cancer; Celastrol; Gamendazole; Gedunin; Heat shock response; Hsp90; Novobiocin

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 7 DESACETYLCARBAMATEGEDUNIN; 7 OXOGEDUNIN; ANTINEOPLASTIC AGENT; AUY 922; CELASTROL; CELL CYCLE PROTEIN 37; CHAPERONE; CNF 2024; GAMENDAZOLE; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NOVOBIOCIN; RADICICOL; ROMIDEPSIN; SNX 5422; TANESPIMYCIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CLINICAL TRIAL; CONTRACEPTION; CYSTIC FIBROSIS; HEAT SHOCK; HUMAN; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; PATHOGENESIS; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VIRUS INFECTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 74249108175     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789895683     Document Type: Review

References (168)

1. Paul, S. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 2008, 30, 1172-1184.
2. Messaed, C.; Rouleau, G. A. Molecular mechanisms underlying polyalanine diseases. Neurobiol. Dis. 2009, 34, 397-405.
3. Thomas, S. R.; Witting, P. K.; Drummond, G. R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox. Signal. 2008, 10, 1713-1753.
4. Clavaguera, F.; Bolmont, T.; Crowther, R. A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A. K.; Staufenbiel, M. B. M.; Jucker, M.; Goedert, M.; Tolnay, M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11, 909-914.
5. Vardiman, J. W. Chronic myelogenous leukemia, BCR-ABL1+. Am. J. Clin. Pathol. 2009, 132, 250-260.
6. Jouret, F.; Devuyst, O. CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch. 2009, 457, 1227-1236.
7. Naidoo, N. The endoplasmic reticulum stress response and aging. Rev. Neurosci. 2009, 20, 23-37.
8. Alcain, F. J.; Villalba, J. M. Sirtuin activators. 19 2009, 4, 403-414.
9. Lehman, N. L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol. 2009, 118, 329-347.
10. Wegele, H.; Muller, L.; Buchner, J. Hsp70 and Hsp90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 2004, 151, 1-44.
11. Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 2005, 146, 769-780.
12. Soo, E. T. L.; Yip, G. W. C.; Lwin, Z. M.; Kumar, S. D.; Bay, B.-H. Heat shock proteins as novel therapeutic targets in cancer. In Vivo 2008, 22, 311-316.
13. Caplan, A. J.; Mandal, A. K.; Theodoraki, M. A. Molecular chaperones and protein kinase quality control. Trends Cell. Biol. 2007, 17, 87-92.
14. Pearl, L. H.; Prodromou, C.; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008, 410, 439-453.
15. Neckers, L.; Tsutsumi, S.; Mollapour, M. Visualizing the twists and turns of a molecular chaperone. Nat. Struct. Mol. Biol. 2009, 16, 235-236.
16. Wandinger, S. K.; Richter, L.; Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283, 18473-18477.
17. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical development of Hsp90 inhibitors. Curr. Cancer Drug Targets 2003, 3, 349-358.
18. Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G. The 90-KDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 1998, 79, 129-168.
19. Maloney, A.; Clarke, P. A.; Workman, P. Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective. Curr. Cancer Drug Targets 2003, 3, 331-341.
20. Solit, D. B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13, 38-43.
21. Stravopodis, D. J.; Margaritis, L. H.; Voutsinas, G. E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr. Med. Chem. 2007, 14, 3122-3138.
22. Bishop, S. C.; Burlison, J. A.; Blagg, B. S. J. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr. Cancer Drug Targets 2007, 7, 369-388.
23. Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. Hsp90 as a target for drug development. ChemMedChem 2006, 1, 1331-1340.
24. Blagg, B. S. J.; Kerr, T. D. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med. Res. Rev. 2006, 26, 310-338.
25. Solit, D. B.; Rosen, N. Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 2006, 6, 1205-1214.
26. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 2008, 15, 2702-2717.
27. Amolins, M. W.; Blagg, B. S. J. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Rev. Med. Chem 2009, 9, 140-152.
28. Tash, J. S.; Chakrasali, R.; Jakkaraj, S. R.; Hughes, J.; Smith, S. K.; Hornbaker, K.; Heckert, L. L.; Ozturk, S. B.; Hadden, M. K.; Kinzy, T. G.; Blagg, B. S. J.; Georg, G. I. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets Hsp90AB1 (Hsp90BETA) and EEF1A1 (eEf1A), and stimulates Il1a transcription in rat sertoli cells. Biol. Reprod. 2008, 78, 1139-1152.
29. Hadden, M. K.; Lubbers, D. J.; Blagg, B. S. J. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr. Top. Med. Chem. 2006, 6, 1173-1182.
30. Workman, P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003, 3, 297-300.
31. Chiosis, G.; Rodina, A.; Moulick, K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med. Chem. 2006, 6, 1-8.
32. Breinig, M.; Caldas-Lopes, E.; Goeppert, B.; Malz, M.; Rieker, R.; Bergmann, F.; Schirmacher, P.; Mayer, M.; Chiosis, G.; Kern, M. A. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009, 50, 102-112.
33. Li, X.; Shocron, E.; Song, A.; Patel, N.; Sun, C. L. Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7, 8-dihydropteridin-6(5H)-ones as potent and selective Hsp90- inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 2860-2864.
34. Hadden, M. K.; Blagg, B. S. J. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. J. Org. Chem. 2009, 74, 4697-4704.
35. Duerfeldt, A. S.; Brandt, G. E. L.; Blagg, B. S. J. Design, synthesis, and biological evaluation of conformationally constrained cisamide Hsp90 inhibitors. Org. Lett. 2009, 11, 2353-2360.
36. Wang, M.; Shen, G.; Blagg, B. S. J. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg. Med. Chem. Lett. 2006, 16, 2459-2462.
37. Shen, G.; Blagg, B. S. J. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org. Lett. 2005, 7, 2157-2160.
38. Clevenger, R. C.; Blagg, B. S. J. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org. Lett. 2004, 6, 4459-4462.
39. Shen, G.; Yu, X. M.; Blagg, B. S. Syntheses of photolabile novobiocin analogues. Bioorg. Med. Chem. Lett. 2004, 14, 5903-5906.
40. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 2005, 127, 12778-12779.
41. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242-248.
42. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
43. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C.-G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7, 162-170.
44. Yi, F.; Regan, L. A novel class of small molecule inhibitors of Hsp90. ACS Chem. Biol. 2008, 3, 645-654.
45. Yi, F.; Zhu, P.; Southall, N.; Inglese, J.; Austin, C. P.; Zheng, W.; Regan, L. An Alphascreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J. Biomol. Screen. 2009, 14, 273-281.
46. Cortajarena, A. L.; Yi, F.; Regan, L. Designed TPR modules as novel anticancer agents. ACS Chem. Biol. 2008, 3, 161-166.
47. Usmani, S. Z.; Bona, R.; Li, Z. 17 AAG for Hsp90 inhibition in cancer--from bench to bedside. Curr. Mol. Med. 2009, 9, 654-664.
48. Tofilon, P. J.; Camphausen, K. Molecular Targets for Tumor Radiosensitization. Chem. Rev. 2009, 109, 2974-2988.
49. Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009, 15, 9-14.
50. Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown, S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II trial of 17-allylamino- 17demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14, 8302-8307.
51. Neckers, L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr. Top. Med. Chem. 2006, 6, 1163-1171.
52. Powers, M. V.; Workman, P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007, 581, 3758-3769.
53. Mahalingam, D.; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting Hsp90 for cancer therapy. Br. J. Cancer 2009, 100, 1523-1529.
54. Matthews, R.; Burnie, J. The role of Hsp90 in fungal infection. Immunol. Today 1992, 13, 345-348.
55. Burnie, J. P.; Carter, T. L.; Hodgetts, S. J.; Matthews, R. C. Fungal heat-shock proteins in human disease. FEMS Microbiol. Rev. 2006, 30, 53-88.
56. Zuehlke, A.; Johnson, J. L. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2009, In Press.
57. Wang, X.; Venable, J.; LaPointe, P.; Hutt, D. M.; Koulov, A. V.; Coppinger, J.; Gurkan, C.; Kellner, W.; Matteson, J.; Plutner, H.; Riordan, J. R.; Kelly, J. W.; Yates, 3rd, J. R.; Balch, W. E. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006, 127, 803-815.
58. Pearl, L. H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271-294.
59. Dutta, R.; Inouye, M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 2000, 25, 24-28.
60. Pratt, W. B.; Morishima, Y.; Osawa, Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 2008, 283, 22885-22889.
61. Voellmy, R.; Boellmann, F. Chaperone Regulation of the Heat Shock Protein Response. In Molecular Aspects of the Stress Response: Chaperones, Membranes and Networks, Csermely, P.; Vigh, L., Eds. Landes Bioscience and Springer Science+Business Media: New York, 2007; Vol. 594, pp 89-99.
62. Powers, M. V.; Workman, P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer 2006, 13, 125-135.
63. Nadeau, K.; Das, A.; Walsh, C. T. Hsp90 chaperonins posses ATPase activity and bind heat shock transcription factors and peptidyl prolyl isomerases. J. Biol. Chem. 1993, 268, 1479-1487.
64. Obermann, W. M. J.; Sondermann, H.; Russo, A. A.; Pavletich, N. P.; Hartl, F. U. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol. 1998, 143, 901-910.
65. Panaretou, B.; Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998, 17, 4829-4836.
66. Prodromou, C.; Siligardi, G.; O'Brien, R.; Woolfson, D. N.; Regan, L.; Panaretou, B.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Regulation of Hsp90 ATPase activity by tetracopeptide repeat (TPR)-domain co-chaperones. EMBO J. 1999, 18, 754-762.
67. Retzlaff, M.; Stahl, M.; Eberl, H. C.; Lagleder, S.; Beck, J.; Kessler, H.; Buchner, J. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 2009, 10(10), 1147-1153.
68. Onuoha, S. C.; Coulstock, E. T.; Grossmann, J. G.; Jackson, S. E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 2008, 379, 732-744.
69. Yun, B. G.; Huang, W.; Leach, N.; Hartson, S. D.; Matts, R. L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interations. Biochemistry 2004, 43, 8217-8229.
70. Hartson, S. D.; Thulasiraman, V.; Huang, W.; Whitesell, L.; Matts, R. L. Molybdate inhibitos Hsp90. induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry 1999, 38, 3837-3849.
71. Hartson, S. D.; Thulasiraman, V.; Huang, W.; Whitesell, L.; Matts, R. L. Molybdate inhibits Hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry 1999, 38, 3837-3849.
72. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Leclerc-Devin, J.; Millot, J.-M.; Briand, C.; Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to heat shock protein 90. J. Biol. Chem. 2002, 277, 12208-12214.
73. Soti, C.; Vermes, A.; Haystead, T. A. J.; Csermely, P. Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site. Eur. J. Biochem. 2003, 270, 2421-2428.
74. Chadli, A.; Bruinsma, E. S.; Stensgard, B.; Toft, D. Analysis of Hsp90 cochaperone interactions reveals a novel mechanism for TPR protein recognition. Biochemistry 2008, 47, 2850-2857.
75. Odunuga, O. O.; Longshaw, V. M.; Blatch, G. L. Hop: more than and Hsp70/Hsp90 adaptor protein. Bioessays 2004, 26, 1058-1068.
76. Chen, S.; Smith, D. F. Hop as an adaptor in the heat shock protein 70 (Hsp70) and Hsp90 chaperone machinery. J. Biol. Chem. 1998, 273, 35194-35200.
77. Davies, T. H.; Sanchez, E. R. FKBP52. Int. J. Biochem. Cell Biol. 2005, 37, 42-47.
78. Caplan, A. J. What is a co-chaperone? Cell Stress and Chaperones 2003, 8, 105-107.
79. Hainzl, O.; Lapina, M. C.; Buchner, J.; Richter, K. The charged linker region is an important regulator of hsp90 function. J. Biol. Chem. 2009, 284, 22559-22567.
80. Hawle, P.; Siepmann, M.; Harst, A.; Siderius, M.; Reusch, H. P.; Obermann, W. M. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell Biol. 2006, 26, 8385-8395.
81. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural and functional analysis of the middle sigment of Hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell. 2003, 11, 647-658.
82. Vaughan, C. K.; Gohlke, U.; Sobott, F.; Good, V. M.; Ali, M. M. U.; Prodromou, C.; Robinson, C. V.; Saibil, H. R.; Pearl, L. H. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 2006, 23, 697-707.
83. Lotz, G. P.; Lin, H.; Harst, A.; Obermann, W. M. J. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J. Biol. Chem. 2003, 278, 17228-17235.
84. Stirling, P. C.; Bakhoum, S. F.; Feigl, A. B.; Leroux, M. R. Convergent evolution of clamp-like binding sites in diverse chaperones. Nat. Struct. Mol. Biol. 2006, 13, 865-870.
85. Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O'Brien, R.; Ladbury, J. E.; Roe, S. M.; Piper, P. W.; Pearl, L. H. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terinal domains. EMBO J. 2000, 19, 4383-4392.
86. Roe, S. M.; Ali, M. M.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P. W. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50cdc37. Cell 2004, 11, 87-98.
87. Cunningham, C. N.; Krukenberg, K. A.; Agard, D. A. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol. Chem. 2008, 283, 21170-21178.
88. Hartson, S. D.; Irwin, A. D.; Shao, J.; Scroggins, B. T.; Volk, L.; Huang, W.; Matts, R. L. p50cdc37 is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry 2000, 39, 7631-7644.
89. Li, Y.; Zhang, T.; Schwartz, S. J.; Sun, D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical prespective and more potential. Drug Resist. Updat. 2009, 12, 17-27.
90. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmcol. 2008, 8, 370-374.
91. Huang, K. H.; Veal, J. M.; Fadden, R. P.; Rice, J. W.; Eaves, J.; Strachan, J. P.; Barabasz, A. F.; Foley, B. E.; Barta, T. E.; Ma, W.; Silinski, M. A.; Hu, M.; Partridge, J. M.; Scott, A.; DuBois, L. G.; Freed, T.; Steed, P. M.; Ommen, A. J.; Smith, E. D.; Hughes, P. F.; Woodward, A. R.; Hanson, G. J.; McCall, W. S.; Markworth, C. J.; Hinkley, L.; Jenks, M.; Geng, L.; Lewis, M.; Otto, J.; Pronk, B.; Verleysen, K.; Hall, S. E. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 2009, 52, 4288-4305.
92. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
93. Koga, F.; Kihara, K.; Neckers, L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009, 29, 797-807.
94. Chiosis, G.; Lopes, E. C.; Solit, D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr. Opin Investig. Drugs 2006, 7, 534-541.
95. Schmitt, E.; Gehrmann, M.; Brunet, M.; Multhoff, G.; Garrido, C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Bio. 2007, 81, 15-27.
96. Pespeni, M.; Hodnett, M.; Pittet, J. F. In vivo stress preconditioning. Methods 2005, 35, 158-164.
97. Shamovsky, I.; Nudler, E. New insights into the mechanism of heat shock response activation. Cell Mol. Life Sci. 2008, 65, 855-861.
98. Guettouche, T.; Boellmann, F.; Lane, W. S.; Voellmy, R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem. 2005, 6, 4.
99. Bagatell, R.; Paine-Murrieta, G. D.; Taylor, C. W.; Pulcini, E. J.; Akinaga, S.; Benjamin, I. J.; Whitesell, L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents. Clin. Cancer Res. 2000, 6, 3312-3318.
100. Lu, Y.; Ansar, S.; Michaelis, M. L.; Blagg, B. S. J. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg. Med. Chem. 2009, 17, 1709-1715.
101. Ansar, S.; Burlison, J. A.; Hadden, M. K.; Yu, X. M.; Desino, K. E.; Bean, J.; Neckers, L.; Audus, K. L.; Michaelis, M. L.; Blagg, B. S. J. A non-toxic Hsp90 inhibitor protects neurons from Abeta-inducted toxicity. Bioorg. Med. Chem. Lett. 2007, 17, 1984-1990.
102. Peterson, L. B.; Blagg, B. S. J. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Medicinal Chemistry 2009, 1, 267-283.
103. Rice, J. W.; Veal, J. M.; Fadden, R. P.; Barabasz, A. F.; Partridge, J. M.; Barta, T. E.; Dubois, L. G.; Huang, K. H.; Mabbett, S. R.; Silinski, M. A.; Steed, P. M.; Hall, S. E. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58, 3765-3775.
104. Stephanou, A.; Latchman, D. S.; Isenberg, D. A. The regulation of heat shock proteins and their role in systemic lupus erythematosus. Semin. Arthritis Rheum. 1998, 28, 155-162.
105. Chatterjee, A.; Black, S. M.; Catravas, J. D. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol. 2008, 49, 134-140.
106. Pittet, J.-F.; Lee, H.; Pespeni, M.; O'Mahony, A.; Roux, J.; Welch, W. J. Stress-induced inhibtion of the NF-kB signaling pathway results from the insolubilization of the IkB kinase complex following its dissociation from heat shock protein 90. J. immunol. 2005, 174, 384-394.
107. Arthur, J. C.; Lich, J. D.; Aziz, R. K.; Kotb, M.; Ting, J. P. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J. Immunol. 2007, 179, 6291-6296.
108. Salminen, A.; Paimela, T.; Suuronen, T.; Kaarniranta, K. Innate immunity meets with cellular stress at the IKK complex: regulation of the IKK complex by Hsp70 and Hsp90. Immunol. Lett. 2008, 117, 9-15.
109. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J. Am. Chem. Soc. 2006, 128, 15529-15536.
110. Palermo, C. M.; Westlake, C. A.; Gasiewicz, T. A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 KDa heat shock protein. Biochemistry 2005, 44, 5041-5052.
111. Itoh, H.; Ogura, M.; Komatsuda, A.; Wakui, H.; Miura, A. B.; Tashima, Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochem. J. 1999, 343, 697-703.
112. Soti, C.; Raez, A.; Csermely, P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. J. Biol. Chem. 2002, 277, 7066-7075.
113. Byrd, C. A.; Bornmann, W.; Erdjument-Bromage, H.; Tempst, P.; Pavletich, N.; Rosen, N.; Nathan, C. F.; Ding, A. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. 1999, 96, 5645-5650.
114. Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res. 2003, 63, 2139-2144.
115. Nichols, R. L.; Finland, M. Novobiocin; a limited bacteriologic and clinical study of its use in forty-five patients. Antibiotic Med. Clin. Ther. 1956, 2, 241-257.
116. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in C-terminal domain of Hsp90. J. Biol. Chem. 2006, 281, 7161-7171.
117. Bras, G. L.; Radanyi, C.; Peyrat, J. F.; Brion, J. D.; Alami, M.; Marsaud, V.; Stella, B.; Renoir, J. M. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 2007, 50, 6189-6200.
118. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J. Org. Chem. 2008, 73, 2130-2137.
119. Radanyi, C.; Bras, G. L.; Messaoudi, S.; Bouclier, C.; Peyrat, J. F.; Brion, J. D.; marsaud, V.; Renoir, J. M.; Alami, M. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (Hsp90). Bioorg. Med. Chem. Lett. 2008, 18, 2495-2498.
120. Radanyi, C.; Bras, G. L.; Bouclier, C.; Messaoudi, S.; Peyrat, J. F.; Brion, J. D.; Alami, M.; Renoir, J. M. Tosylcyclonovobioci acids promote cleavage of the hsp90-associated cochaperone p23. Biochem. Biophys. Res. Commun. 2009, 379, 514-518.
121. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, g.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J. Org. Chem. 2008, 73, 8901-8920.
122. Caplan, A. J.; Ayan, A. M.; Wilis, I. M. Multiple kinases and system robustness: a link between Cdc37 and genome integrity. Cell Cycle 2007, 6, 3145-3147.
123. Vaughn, C. K.; Mollapour, M.; Smith, J. R.; Truman, A.; Hu, B.; Good, V. M.; Panaretou, B.; Neckers, L.; Clarke, P. A.; Workman, P.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 2008, 31, 886-895.
124. Grammatikakis, N.; Lin, J. H.; Grammatikakis, A.; Tsichlis, P. N.; Cochran, B. H. p50cdc37 acting in concert with Hsp90 is required for Raf-1 function. Mol. Cell. Biol. 1999, 19, 1661-1672.
125. Karnitz, L. M.; Felts, S. J. Regulation of the kinome: when to hold 'em and when to fold 'em. STKE 2007, pe22, 1-3.
126. Pearl, L. H. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 2005, 15, 55-61.
127. Gray, P. J. J.; Prince, T.; Cheng, J.; Stevenson, M. A.; Calderwood, S. K. Targeting the oncogene and kinome chaperone Cdc37. Nat. Rev. Cancer 2008, 8, 491-495.
128. Smith, J. R.; Workman, P. Targeting Cdc37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009, 8, 362-372.
129. Gray, P. J. J.; Stevenson, M. A.; Calderwood, S. K. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 2007, 67, 11942-11950.
130. Smith, J. R.; Clarke, P. A.; Billy, E. D.; Workman, P. Silencing the cochaperone Cdc37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors. Oncogene 2008, 28, 157-169.
131. Setty, A. R.; Sigal, L. H. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin. Arthritis Rheum. 2005, 34, 773-784.
132. Sreeramulu, S.; Gande, S. L.; Gobel, M.; Schwalbe, H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew. Chem. Int. Ed. 2009, 48, 5853-5855.
133. Trott, A.; West, J. D.; Klaic, L.; Westerheide, S. D.; Silverman, R. B.; Morimoto, R. I.; Morano, K. A. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 2008, 19, 1104-1112.
134. Westerheide, S. D.; Bosman, J. D.; Mbadugha, B. N.; Kawahara, T. L.; Matsumoto, G.; Kim, S.; Gu, W.; Devlin, J. P.; Silverman, R. B.; Morimoto, R. I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 204, 279, 56053-56060.
135. Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, i. C.; Wrobel, M. J.; Lerner, J.; Brunet, J.-P.; Subramanian, A.; Ross, K. N.; Reich, M.; hieronymus, h.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313, 1929-1935.
136. Hieronymus, H.; lamb, J.; Ross, K. N.; Peng, X. P.; Clement, C.; Rodina, A.; nieto, M.; Du, J.; Stegmaier, K.; Raj, S. M.; Maloney, K. N.; Clardy, J.; Hahn, W. C.; Chiosis, G.; Golub, t. R. Gene expression signature-based chemical genomic prediction identifies a novel class of Hsp90 pathway modulators. Cancer Cell 2006, 10, 321-330.
137. Subapriya, R.; Nagini, S. Medicinal properties of neem leaves: a review. Curr. Med. Chem. Anticancer Agents 2005, 5, 149-156.
138. Brahmachari, G. Neem - an omnipotent plant: a retrospection. Chembiochem 2004, 5, 408-421.
139. Yang, H.; Chen, D.; Cui, Z. C.; Yuan, X.; Dou, W. P. Celastrol, a triterpene extracted from the chinese "thunder of god vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66, 4758-4765.
140. Brandt, G. E. L.; Schmidt, M. D.; Prisinzano, T. E.; Blagg, B. S. J. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem. 2008, 51, 6495-6502.
141. Balick, M. J.; Lee, R. Digging in the herb garden: responding to a patient's query about thunder of god vine. Altern. Ther. Health Med. 2001, 7, 100-103.
142. Aladakatti, R. H.; Ahamed, R. N. Ultrastructural changes in leydig cells and cauda epididymal spematozoa induced by azadirachta indica leaves in albino rats. Phytother. Res. 2005, 19, 756-766.
143. Plescla, J.; Salz, W.; Xia, F.; Pennati, m.; Zaffaroni, N.; Daidone, M. G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D. I.; Colombo, G.; Altieri, D. C. Rational design of Shepheridin, a novel anticancer agent. Cancer Cell 2005, 7, 457-468.
144. Scroggins, B. T.; Robzyk, K.; Wang, D.; Marcu, M. G.; Tsutsumi, s.; Beebe, K.; Cotter, R. J.; Felts, S.; Toft, D.; Karnitz, L.; Rosen, N.; Neckers, L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 2007, 25, 151-159.
145. Thomas, S.; Munster, P. N. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009, 280, 184-191.
146. Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucogorticoid receptor. Mol. Cell 2005, 18, 601-607.
147. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J. E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112, 1886-1893.
148. Kekatpure, V. D.; Dannenberg, A. J.; Subbaramaiah, K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 2009, 284, 7436-7445.
149. Fiskus, W.; Ren, Y.; Mohapatra, A.; Bali, P.; Mandawat, A.; Rao, R.; Herger, B.; Yang, Y.; Atadja, P.; Wu, J.; Bhalla, K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-a levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer Res. 2007, 13, 4882-4890.
150. Wang, Y.; Wang, S.-Y.; Zhang, X.-H.; Zhao, M.; Hou, C.-M.; Xu, Y.-J.; Du, Z.; Yu, X.-D. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Commun. 2007, 356, 2007.
151. Nguyen, A.; Su, L.; Campbell, B.; Poulin, N. M.; Nielsen, T. O. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009, 2009, in press.
152. Neckers, L.; Tatu, U. Molecular chaperones in pathogen virulence: emergin new targets for therapy. Cell Host Microbe 2008, 4, 519-527.
153. Cowen, L. E.; Steinback, W. J. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 2008, 7, 747-764.
154. Cowen, L. E.; Singh, S. D.; Kohler, J. R.; Collins, C.; Zaas, A. K.; Schell, W. A.; Aziz, H.; Mylonakis, E.; Perfect, J. R.; Whitesell, L.; Lindquist, S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. USA 2009, 106, 2818-2823.
155. Semighini, C. P.; Heitman, J. Dynamic duo takes down fungal villains. Proc. Natl. Acad. Sci. USA 2009, 106, 2971-2972.
156. Matthews, R. C.; Burnie, J. P. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004, 22, 865-871.
157. Lopatin, D. E.; Combs, A.; Sweier, D. G.; Fenno, J. C.; Dhamija, S. Characterization of heat-inducible expression and cloning of HtpG (Hsp90 homologue) of Porphyromonas gingivalis. Infect. Immun. 2000, 68, 1980-1987.
158. Acharya, P.; Kumar, R.; Tatu, U. Chaperoning a cellular upheaval in malaria: heat shock proteins in Plasmodium falciparum. Mol. Biochem. Parasitol. 2007, 153, 85-94.
159. Pavithra, S. R.; Kumar, R.; Tatu, U. Systems analysis of chaperone networks in the malarial parasite Plasmodium falciparum. PLoS Comput. Biol. 2007, 3, 1701-1715.
160. Lund, P. A. Microbial molecular chaperones. Adv. Microb. Physiol. 2001, 44, 93-140.
161. Arsene, F. The heat shock response of Escherichia coli. Int. J. Food Microbiol. 2000, 55, 3-9.
162. Valle, J. R.-d.; Chavez-Salinas, S.; Medina, F.; Angel, R. M. d. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J. Virol. 2005, 79, 4557-4567.
163. Ujino, S.; Yamaguchi, S.; Shimotohno, K.; Takaku, H. Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J. Biol. Chem. 2009, 284, 6841-6846.
164. Chase, G.; Deng, T.; Fodor, E.; Leung, B. W.; Mayer, D.; Schwemmle, M.; Brownlee, G. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 2008, 377, 431-439.
165. Dutta, D.; Bagchi, P.; Chatterjee, A.; Nayak, M. K.; Mukherjee, A.; Chattopadhyay, S.; Nagashima, S.; Kobayashi, N.; Komoto, S.; Taniguchi, K.; Chawla-Sarkar, M. The molecular chaperone heat shock protein-90 positively regulates rotavirus infectionx. Virology 2009, 391, 325-333.
166. Amaral, M. D. Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease. J. Inherit. Metab. Dis. 2006, 29, 477-487.
167. Fuller, W.; Cuthbert, A. W. Post-translational disruption of the DF508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes DF508 CFTR in the rabbit reticulocyte lysate. J. Biol. Chem. 2000, 275, 37462-37468.
168. Sun, F.; Mi, Z.; Condliffe, S. B.; Bertrand, C. A.; Gong, X.; Lu, X.; Zhang, R.; Latoche, J. D.; Pilewski, J. M.; Robbins, P. D.; Frizzell, R. A. Chaperone displacement from mutant cystic fibrosis transmembrande conductance regulator restores its function in human airway epithelia. FASEB J. 2008, 22, 3255-3263.